1
|
Reinig S, Kuo C, Wu CC, Huang SY, Yu JS, Shih SR. Specific long-term changes in anti-SARS-CoV-2 IgG modifications and antibody functions in mRNA, adenovector, and protein subunit vaccines. medRxiv 2024:2023.06.16.23291455. [PMID: 38559243 PMCID: PMC10980124 DOI: 10.1101/2023.06.16.23291455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/04/2024]
Abstract
Various vaccine platforms were developed and deployed against the COVID-19 disease. The Fc-mediated functions of IgG antibodies are essential in the adaptive immune response elicited by vaccines. However, the long-term changes of protein subunit vaccines and their combinations with mRNA vaccines are unknown. A total of 272 serum and plasma samples were collected from individuals who received first to third doses of the protein subunit Medigen, the mRNA (BNT), or the adenovector AstraZeneca vaccines. The IgG subclass level was measured using enzyme-linked immunosorbent assay, and Fc-N glycosylation was measured using LC-MS/MS. Antibody-dependent phagocytosis (ADCP) and complement deposition (ADCD) of anti-spike (S) IgG antibodies were measured. IgG1 and 3 reached the highest anti-S IgG subclass level. IgG1, 2, and 4 subclass levels significantly increased in mRNA- and Medigen-vaccinated individuals. Fc-glycosylation was stable, except in female BNT vaccinees, who showed increased bisection and decreased galactosylation. Female BNT vaccinees had a higher anti-S IgG titer than that of males. ADCP declined in all groups. ADCD increased in Medigen-vaccinated individuals after the third dose. Each vaccine produced specific long-term changes in Fc structure and function. This finding is critical when selecting a vaccine platform or combination to achieve the desired immune response.
Collapse
Affiliation(s)
- Sebastian Reinig
- Research center for Emerging viral infections, Chang Gung University, Taoyuan, Taiwan
| | - Chin Kuo
- Research center for Emerging viral infections, Chang Gung University, Taoyuan, Taiwan
| | - Chia-Chun Wu
- Molecular research center, Chang Gung University, Taoyuan
| | - Sheng-Yu Huang
- Research center for Emerging viral infections, Chang Gung University, Taoyuan, Taiwan
| | - Jau-Song Yu
- Molecular research center, Chang Gung University, Taoyuan
- Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan
- Liver Research Center, Chang Gung Memorial Hospital, Linkou 33305, Taiwan
- Research Center for Food and Cosmetic Safety, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan 33302, Taiwan
| | - Shin-Ru Shih
- Research center for Emerging viral infections, Chang Gung University, Taoyuan, Taiwan
- Department of Laboratory Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan
- Research Center for Chinese Herbal Medicine, Research Center for Food and Cosmetic Safety, Graduate Institute of Health Industry Technology, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan, Taiwan
- Department of Medical Biotechnology and Laboratory Science, Chang Gung University, Taoyuan, Taiwan
- Clinical Virology Laboratory, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
| |
Collapse
|
2
|
Ptushkin V, Arshanskaya E, Vinogradova O, Kudlay D, Nikitin E. The Features of COVID-19's Course and the Efficacy of the Gam-COVID-Vac Vaccine in Patients with Paroxysmal Nocturnal Hemoglobinuria. Hematol Rep 2023; 15:503-512. [PMID: 37754667 PMCID: PMC10531158 DOI: 10.3390/hematolrep15030052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2023] [Revised: 07/14/2023] [Accepted: 07/24/2023] [Indexed: 09/28/2023] Open
Abstract
COVID-19 and other infectious diseases can exacerbate the course of paroxysmal nocturnal hemoglobinuria (PNH). The efficacy and safety of the Gam-COVID-Vac vaccine in patients with PNH has not been adequately studied. A retrospective, observational, cohort, non-comparative study was performed to assess the course of COVID-19 as well as the safety and efficacy of the Gam-COVID-Vac (Sputnik V) vaccine in patients with paroxysmal nocturnal hemoglobinuria (PNH). The study included data from 52 patients with PNH aged 18 to 75 years, 38 of whom received background therapy with eculizumab (Elizaria®) between March 2020 and January 2022. COVID-19 was diagnosed according to the results of PCR testing. The patients were divided into two groups for comparison of the incidence of COVID-19. Group 1 included non-vaccinated patients with PNH, and Group 2 included patients vaccinated prior to the onset of COVID-19. According to vaccination, patients were subdivided into non-vaccinated and vaccinated groups without signs of previous COVID-19 at the beginning of the analyzed period, and patients vaccinated half a year or more after recovery from COVID-19. Testing for anti-SARS-CoV-2 IgG levels was carried out in patients with PNH in the year after their COVID-19. Tests for anti-SARS-CoV-2 RBD IgG levels were performed on vaccinated patients. In total, 28 (53.8%) of the enrolled patients had COVID-19, including asymptomatic forms in 7 (25%) and mild forms in 16 (57%) patients. A total of 22 (42.3%) patients were fully vaccinated with Gam-COVID-Vac, of which 13 (25%) patients were vaccinated without the signs of previous SARS-CoV-2infection, and 9 (17.3%) patients were vaccinated after COVID-19. The number of patients who had COVID-19 was about two times higher in Group 1 (non-vaccinated; 24) (61.5%), whereas in Group 2 (vaccinated), the number of patients with COVID-19 was only 4 (30.8%). The proportion and number of patients who did not have COVID-19 was higher in the group of vaccinated patients (9; 69.2%) than in the group of non-vaccinated patients (15; 38.5%) (p = 0.054). In patients who had been infected with COVID-19, maximum concentrations of anti-SARS-CoV-2 IgG were observed 2-3 months after the acute infection phase, followed by a gradual decline by month 9-10. The mean RBD IgG concentration was higher in the group of patients who had been infected by COVID-19 than in the group of patients without COVID-19 (p = 0.047). Therapy type, including eculizumab, did not have a significant impact on RBD IgG titers (p > 0.05). Hospitalization was required in five (18%) patients, all of whom had breakthrough hemolysis and severe lung damage on CT scans. After the first dose, adverse events (AEs) were reported in 41% of the patients (body temperature increased in 18%; headache in 13.6%; and pain in joints in 4.5%; colitis exacerbation was observed in 4.5%). After the second dose, no AEs were reported. The performed study suggests the possible efficacy and demonstrates the safety of Gam-COVID-Vac (Sputnik V) for the prophylaxis of COVID-19 in patients with PNH who experience immunosuppression due to target therapy.
Collapse
Affiliation(s)
- Vadim Ptushkin
- Moscow City Hematology Center, S.P. Botkin City Clinical Hospital, Moscow 125284, Russia
- Department of Oncology, Hematology and Radiation Therapy, Pirogov Russian National Research Medical University, Moscow 117997, Russia
| | - Evgeniya Arshanskaya
- Moscow City Hematology Center, S.P. Botkin City Clinical Hospital, Moscow 125284, Russia
| | - Olga Vinogradova
- Moscow City Hematology Center, S.P. Botkin City Clinical Hospital, Moscow 125284, Russia
- Department of Oncology, Hematology and Radiation Therapy, Pirogov Russian National Research Medical University, Moscow 117997, Russia
| | - Dmitry Kudlay
- Department of Pharmacology, Pharmacy Institute, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia
| | - Eugene Nikitin
- Moscow City Hematology Center, S.P. Botkin City Clinical Hospital, Moscow 125284, Russia
- Hematology and Transfusiology Department, Russian Medical Academy of Continuous Professional Education, Moscow 125993, Russia
| |
Collapse
|
3
|
Jarupan M, Jantarabenjakul W, Jaruampornpan P, Subchartanan J, Phasomsap C, Sritammasiri T, Cartledge S, Suchartlikitwong P, Anugulruengkitt S, Kawichai S, Puthanakit T. Long COVID and Hybrid Immunity among Children and Adolescents Post-Delta Variant Infection in Thailand. Vaccines (Basel) 2023; 11:vaccines11050884. [PMID: 37242988 DOI: 10.3390/vaccines11050884] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2023] [Revised: 04/18/2023] [Accepted: 04/20/2023] [Indexed: 05/28/2023] Open
Abstract
This study aimed to assess long COVID, and describe immunogenicity against Omicron variants following BNT162b2 vaccination. A prospective cohort study was conducted among children (aged 5-11) and adolescents (aged 12-17) who had SARS-CoV-2 infection from July to December 2021 (Delta predominant period). Long COVID symptoms were assessed by questionnaires at 3 months after infection. Immunogenicity was evaluated by using a surrogate virus-neutralizing antibody test (sVNT) against the Omicron variant. We enrolled 97 children and 57 adolescents. At 3 months, 30 children (31%) and 34 adolescents (60%) reported at least one long COVID symptom, with respiratory symptoms prevailing (25% children and 32% adolescents). The median time from infection to vaccination was 3 months in adolescents and 7 months in children. At 1 month following vaccination, in children who received one-dose and two-dose BNT162b2 vaccines, the median (IQR) sVNT against Omicron was 86.2% inhibition (71.1-91.8) and 79.2% inhibition (61.5-88.9), respectively (p = 0.26). Among adolescents who received one-dose and two-dose BNT162b2 vaccines, the median (IQR) sVNT against Omicron was 64.4% inhibition (46.8-88.8) and 68.8% inhibition (65.0-91.2) (p = 0.64). Adolescents had a higher prevalence of long COVID than children. Immunogenicity against the Omicron variant after vaccination was high and did not vary between one or two doses of the vaccine in either children or adolescents.
Collapse
Affiliation(s)
- Muttharat Jarupan
- Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
| | - Watsamon Jantarabenjakul
- Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
- Center of Excellence for Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Chulalongkorn University, Bangkok 10330, Thailand
- Thai Red Cross Emerging Infectious Diseases Clinical Center, King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand
| | - Peera Jaruampornpan
- Monoclonal Antibody Production and Application Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC), Pathum Thani 12120, Thailand
| | - Jarujan Subchartanan
- Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
| | - Chayapa Phasomsap
- Center of Excellence for Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Chulalongkorn University, Bangkok 10330, Thailand
| | - Taweesak Sritammasiri
- Center of Excellence for Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Chulalongkorn University, Bangkok 10330, Thailand
| | | | - Pintip Suchartlikitwong
- Center of Excellence for Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Chulalongkorn University, Bangkok 10330, Thailand
- Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
| | - Suvaporn Anugulruengkitt
- Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
- Center of Excellence for Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Chulalongkorn University, Bangkok 10330, Thailand
| | - Surinda Kawichai
- Center of Excellence for Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Chulalongkorn University, Bangkok 10330, Thailand
| | - Thanyawee Puthanakit
- Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
- Center of Excellence for Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Chulalongkorn University, Bangkok 10330, Thailand
| |
Collapse
|
4
|
Svačina MKR, Meißner A, Schweitzer F, Ladwig A, Sprenger‐Svačina A, Klein I, Wüstenberg H, Kohle F, Schneider C, Grether NB, Wunderlich G, Fink GR, Klein F, Di Cristanziano V, Lehmann HC. Antibody response after COVID-19 vaccination in intravenous immunoglobulin-treated immune neuropathies. Eur J Neurol 2022; 29:3380-3388. [PMID: 35842740 PMCID: PMC9349681 DOI: 10.1111/ene.15508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2022] [Revised: 06/24/2022] [Accepted: 07/13/2022] [Indexed: 11/29/2022]
Abstract
BACKGROUND AND PURPOSE This study assessed the prevalence of anti-SARS-CoV-2 antibodies in therapeutic immunoglobulin and their impact on serological response to COVID-19 mRNA vaccine in patients with intravenous immunoglobulin (IVIg)-treated chronic immune neuropathies. METHODS Forty-six samples of different brands or lots of IVIg or subcutaneous IgG were analyzed for anti-SARS-CoV-2 IgG using enzyme-linked immunosorbent assay and chemiluminescent microparticle immunoassay. Blood sera from 16 patients with immune neuropathies were prospectively analyzed for anti-SARS-CoV-2 IgA, IgG, and IgM before and 1 week after IVIg infusion subsequent to consecutive COVID-19 mRNA vaccine doses and after 12 weeks. These were compared to 42 healthy subjects. RESULTS Twenty-four (52%) therapeutic immunoglobulin samples contained anti-SARS-CoV-2 IgG. All patients with immune neuropathies (mean age = 65 ± 16 years, 25% female) were positive for anti-SARS-CoV-2 IgG after COVID-19 vaccination. Anti-SARS-CoV-2 IgA titers significantly decreased 12-14 weeks after vaccination (p = 0.02), whereas IgG titers remained stable (p = 0.2). IVIg did not significantly reduce intraindividual anti-SARS-CoV-2 IgA/IgG serum titers in immune neuropathies (p = 0.69). IVIg-derived anti-SARS-CoV-2 IgG did not alter serum anti-SARS-CoV-2 IgG decrease after IVIg administration (p = 0.67). CONCLUSIONS Our study indicates that IVIg does not impair the antibody response to COVID-19 mRNA vaccine in a short-term observation, when administered a minimum of 2 weeks after each vaccine dose. The infusion of current IVIg preparations that contain anti-SARS-CoV-2 IgG does not significantly alter serum anti-SARS-CoV-2 IgG titers.
Collapse
Affiliation(s)
- Martin K. R. Svačina
- Department of Neurology, Faculty of Medicine and University Hospital of CologneUniversity of CologneCologneGermany
| | - Anika Meißner
- Department of Neurology, Faculty of Medicine and University Hospital of CologneUniversity of CologneCologneGermany
| | - Finja Schweitzer
- Department of Neurology, Faculty of Medicine and University Hospital of CologneUniversity of CologneCologneGermany
| | - Anne Ladwig
- Department of Neurology, Faculty of Medicine and University Hospital of CologneUniversity of CologneCologneGermany
| | - Alina Sprenger‐Svačina
- Department of Neurology, Faculty of Medicine and University Hospital of CologneUniversity of CologneCologneGermany
| | - Ines Klein
- Department of Neurology, Faculty of Medicine and University Hospital of CologneUniversity of CologneCologneGermany
| | - Hauke Wüstenberg
- Department of Neurology, Faculty of Medicine and University Hospital of CologneUniversity of CologneCologneGermany
| | - Felix Kohle
- Department of Neurology, Faculty of Medicine and University Hospital of CologneUniversity of CologneCologneGermany
| | - Christian Schneider
- Department of Neurology, Faculty of Medicine and University Hospital of CologneUniversity of CologneCologneGermany
| | - Nicolai B. Grether
- Department of Neurology, Faculty of Medicine and University Hospital of CologneUniversity of CologneCologneGermany
| | - Gilbert Wunderlich
- Department of Neurology, Faculty of Medicine and University Hospital of CologneUniversity of CologneCologneGermany
| | - Gereon R. Fink
- Department of Neurology, Faculty of Medicine and University Hospital of CologneUniversity of CologneCologneGermany
- Cognitive Neuroscience, Research Center JuelichInstitute of Neuroscience and Medicine (INM‐3)JuelichGermany
| | - Florian Klein
- Institute of Virology, Faculty of Medicine and University Hospital of CologneUniversity of CologneCologneGermany
- German Center for Infection Research (DZIF), partner site Bonn‐CologneCologneGermany
| | - Veronica Di Cristanziano
- Institute of Virology, Faculty of Medicine and University Hospital of CologneUniversity of CologneCologneGermany
| | - Helmar C. Lehmann
- Department of Neurology, Faculty of Medicine and University Hospital of CologneUniversity of CologneCologneGermany
| |
Collapse
|
5
|
Assavavongwaikit P, Chantasrisawad N, Himananto O, Phasomsap C, Klawaja P, Cartledge S, Nadsasarn R, Jupimai T, Kawichai S, Anugulruengkitt S, Puthanakit T, On Behalf Of The Study Team. Immunogenicity of BNT162b2 Vaccination against SARS-CoV-2 Omicron Variant and Attitudes toward a COVID-19 Booster Dose among Healthy Thai Adolescents. Vaccines (Basel) 2022; 10:1098. [PMID: 35891264 DOI: 10.3390/vaccines10071098] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2022] [Revised: 06/28/2022] [Accepted: 07/06/2022] [Indexed: 02/06/2023] Open
Abstract
Despite the BNT162b2 vaccination coverage, rapid transmission of Omicron SARS-CoV-2 has occurred, which is suspected to be due to the immune escape of the variant or waning vaccine efficacy of multiple BNT162b2 vaccination doses. Our study aims to compare immunogenicity against Omicron prior to and post a booster dose of BNT162b2 in healthy adolescents, and to evaluate their attitudes toward booster dose vaccination. A cross sectional study was conducted among healthy adolescents aged 12–17 who received two doses of BNT162b2 more than 5 months ago. Participants and their guardians performed self-reported questionnaires regarding reasons for receiving the booster. A 30 ug booster dose of BNT162b2 was offered. Immunogenicity was evaluated by a surrogate virus neutralization test (sVNT) against the Omicron variant, and anti-spike-receptor-binding-domain IgG (anti-S-RBD IgG) taken pre-booster and 14-days post-booster. From March to April 2022, 120 healthy Thai adolescents with a median age of 15 years (IQR 14–16) were enrolled. sVNT against Omicron pre- and post-booster had 11.9 (95%CI 0–23.9) and 94.3 (90.6–97.4) % inhibition. Geometric means (GMs) of anti-S-RBD IgG increased from 837 (728, 953) to 3041 (2893, 3229) BAU/mL. Major reasons to receive the booster vaccination were perceived as vaccine efficacy, reduced risk of spreading infection to family, and safe resumption of social activities. A booster dose of BNT162b2 elicits high immunogenicity against the Omicron variant. Motivation for receiving booster doses is to reduce risk of infection.
Collapse
|
6
|
Almaeen AH, Alduraywish AA, Ghazy AA, El-Metwally TH, Alayyaf M, Alrayes FH, Alinad AKM, Albulayhid SBH, Aldakhil AR, Taha AE. The Pre-Vaccination Donated Blood Is Free from Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) but Is Rich with Anti-SARS-CoV-2 Antibodies: A Cross-Section Saudi Study. Int J Environ Res Public Health 2022; 19:ijerph19127119. [PMID: 35742368 PMCID: PMC9223027 DOI: 10.3390/ijerph19127119] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 04/21/2022] [Revised: 05/30/2022] [Accepted: 06/08/2022] [Indexed: 02/06/2023]
Abstract
(1) Backgrounds and Objectives: Since its discovery, information about the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) has spread rapidly. However, many issues remain unresolved. Coronaviruses are primarily transmitted through respiratory secretions. The possibility of transmission via donated blood transfusion deserves studying. This is the first study in Saudi Arabia to look at pre-vaccination donated blood anti-SARS-CoV-2 antibody content as a marker for virus transmission via viral RNA positive blood and/or the potential therapeutic value of convalescent plasma. (2) Methods: A total of 300 blood samples were sequentially collected from unvaccinated donors who donated blood to the blood bank of Prince Mutaib Bin Abdulaziz Hospital in Sakaka, Al-Jouf, Saudi Arabia. Specific ELISA was used to detect anti-SARS-CoV-2 IgG and IgM antibodies. SARS-CoV-2 was detected using specific real-time reverse-transcription PCR (rRT-PCR). (3) Results: The prevalence of anti-SARS-CoV-2 IgG was low (9%), whereas the prevalence of anti-SARS-CoV-2 IgM was high (65%). Relevant demographics, anthropometrics, and lifestyle factors revealed significant associations (p < 0.05) between IgM-positivity only vs. age (age group 21−30 years), postgraduate education, no history of international travel, IgG-negativity, and absence of experience with COVID-19-like symptoms. Furthermore, there are significant associations (p < 0.05) between IgG-positivity only vs. age (age group 21−30 years), postgraduate education, and being a non-healthcare worker. All donors in the anti-SARS-CoV-2 IgG-positive group (n = 27) had previously experienced symptoms similar to COVID-19 (p < 0.001) and most of them (n = 24) showed anti-SARS-CoV-2 IgM-positive test (p = 0.006). However, all the samples tested negative for SARS-CoV-2 RNA using rRT-PCR. (4) Conclusion: Our findings add to the growing body of evidence that donated blood is safe, with the added benefit of convalescent plasma rich in potentially neutralizing IgG and IgM against SARS-CoV-2.
Collapse
Affiliation(s)
- Abdulrahman H. Almaeen
- Department of Pathology, College of Medicine, Jouf University, Sakaka 72388, Saudi Arabia;
| | | | - Amany A. Ghazy
- Microbiology and Immunology Division, Department of Pathology, College of Medicine, Jouf University, Sakaka 72388, Saudi Arabia; (A.A.G.); (A.E.T.)
- Department of Microbiology & Medical Immunology, Faculty of Medicine, Kafrelsheikh University, Kafrelsheikh 33516, Egypt
| | - Tarek H. El-Metwally
- Department of Pathology, Biochemistry Division, College of Medicine, Jouf University, Sakaka 72388, Saudi Arabia;
- Department of Medical Biochemistry, Faculty of Medicine, Assiut University, Assiut 71517, Egypt
| | - Mohammad Alayyaf
- Prince Mutaib Bin Abdulaziz Hospital, Sakaka 72388, Saudi Arabia;
| | - Fahad Hammad Alrayes
- College of Medicine, Jouf University, Sakaka 72388, Saudi Arabia; (F.H.A.); (A.K.M.A.); (S.B.H.A.); (A.R.A.)
| | - Ahmed Khalid M. Alinad
- College of Medicine, Jouf University, Sakaka 72388, Saudi Arabia; (F.H.A.); (A.K.M.A.); (S.B.H.A.); (A.R.A.)
| | | | - Abdulrhman Rabea Aldakhil
- College of Medicine, Jouf University, Sakaka 72388, Saudi Arabia; (F.H.A.); (A.K.M.A.); (S.B.H.A.); (A.R.A.)
| | - Ahmed E. Taha
- Microbiology and Immunology Division, Department of Pathology, College of Medicine, Jouf University, Sakaka 72388, Saudi Arabia; (A.A.G.); (A.E.T.)
- Medical Microbiology and Immunology Department, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt or
- Correspondence: or or
| |
Collapse
|
7
|
Nantanee R, Jantarabenjakul W, Jaru-Ampornpan P, Sodsai P, Himananto O, Athipunjapong J, Sophonphan J, Nanthapisal S, Hirankarn N, Puthanakit T. A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222. Vaccines (Basel) 2022; 10:vaccines10060914. [PMID: 35746522 PMCID: PMC9230769 DOI: 10.3390/vaccines10060914] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2022] [Revised: 06/02/2022] [Accepted: 06/06/2022] [Indexed: 12/04/2022] Open
Abstract
In the era of globally predominant omicron strains, a COVID-19 booster vaccine is needed. Our study aimed to evaluate the immunogenicity of a half-dose BNT162b2 booster after AZD1222 in healthy adults. A randomized trial of volunteers aged 18–69 years who received two-dose AZD1222 was conducted. The participants were randomized to receive the BNT162b2 vaccine intramuscularly—half (15 µg) vs. standard dose (30 µg). The immunogenicity was evaluated by a surrogate virus neutralization test (sVNT) against omicron variants and anti-spike-receptor-binding-domain IgG (anti-S-RBD IgG). From November–December 2021, 100 adults with a median age of 59.3 years (IQR 33.4–65.5) were enrolled. A booster dose was given at median of 98 days (IQR 92–128) after AZD1222. At day 14, the geometric means (GMs) of anti-S-RBD IgG in half- vs. standard-dose group were 2329.8 vs. 2574.7 BAU/mL, with a geometric mean ratio (GMR) of 0.90 (0.77–1.06). The GMs of sVNT against the omicron variant in the half- and standard-dose groups were 74.4% inhibition (95% CI 68.8–80.5) and 67.3% inhibition (57.9–78.1), respectively, with GMR of 0.95 (0.69–1.30). At day 90, the sVNT indicated 22.3% inhibition (95% CI 14.9–33.4) and 20.4% inhibition (13.1–32.0), respectively, with GMR of 1.09 (0.60–1.98). The fractional low-dose BNT162b2 mRNA booster vaccine provided non-inferior immunogenicity responses. During a shortage of vaccine supply, a fractional low dose should be considered for a booster vaccination program.
Collapse
Affiliation(s)
- Rapisa Nantanee
- Center of Excellence in Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand; (R.N.); (W.J.); (J.A.)
- Pediatric Allergy and Clinical Immunology Research Unit, Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
| | - Watsamon Jantarabenjakul
- Center of Excellence in Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand; (R.N.); (W.J.); (J.A.)
- Thai Red Cross Emerging Infectious Diseases Clinical Center, King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand
| | - Peera Jaru-Ampornpan
- Virology and Cell Technology Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC), Pathum Thani 12120, Thailand;
| | - Pimpayao Sodsai
- Center of Excellence in Immunology and Immune-Mediated Diseases, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand;
| | - Orawan Himananto
- Monoclonal Antibody Production and Application Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC), Pathum Thani 12120, Thailand;
| | - Jitthiwa Athipunjapong
- Center of Excellence in Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand; (R.N.); (W.J.); (J.A.)
| | - Jiratchaya Sophonphan
- The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), The Thai Red Cross AIDS Research Centre, Bangkok 10330, Thailand;
| | - Sira Nanthapisal
- Department of Pediatrics, Faculty of Medicine, Thammasat University, Pathum Thani 12120, Thailand;
| | - Nattiya Hirankarn
- Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand;
| | - Thanyawee Puthanakit
- Center of Excellence in Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand; (R.N.); (W.J.); (J.A.)
- Correspondence: ; Tel.: +66-2-2564930
| |
Collapse
|
8
|
Kaygusuz S, Korukluoğlu G, Coşgun Y, Şahin Ö, Arslan F. INVESTIGATION AND LONG-TERM MONITORING OF THE PRESENCE OF NEUTRALIZING ANTIBODY IN PATIENTS WITH COVID-19 DISEASE OF DIFFERENT CLINICAL SEVERITY. J Med Virol 2022; 94:3596-3604. [PMID: 35365870 DOI: 10.1002/jmv.27751] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2022] [Accepted: 03/28/2022] [Indexed: 01/08/2023]
Abstract
OBJECTIVES Understanding the immune responses elicited by SARS-CoV-2 infection is critical to public health policy and vaccine development and prevention of reinfections for COVID-19. It is important to know the neutralizing capacity of antibodies and to monitor their persistence. METHODS Patients with Covid-19 were divided into four groups (severe-critical, moderate, mild and asymptomatic) according to their clinical severity. Antibodies against SARS-CoV-2 Spike viral surface protein were investigated by ELISA method 3 months and 9 months after the onset of the disease. Neutralizing antibody (NAb) response was evaluated by microneutralization test. Patients who received at least two doses of COVID-19 vaccine after illness were enrolled. RESULTS SARS-CoV-2 IgG and NAb titers were shown to be strongly correlated with disease severity. Anti-SARS-CoV-2 IgG and neutralizing antibody levels were found to be compatible with each other. After 9 months of follow-up, both IgG and NA levels continued unabated in individuals who had the disease. In individuals who received at least two doses of the vaccine, these levels increased, except for severe-critical patients. CONCLUSIONS High levels of anti-SARS-CoV-2 IgG are indicative, as it is difficult to investigate NAb in routine laboratories. At the same time, it can be predicted that this period may be much longer if it continues for at least 9 months and is reinforced with vaccination. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Sedat Kaygusuz
- Kırıkkale University Faculty of Medicine, Department of Infection Disease and Clinical Microbiology, Kirikkale, Turkey
| | - Gülay Korukluoğlu
- Republic of Turkey Ministry of Health, General Directorate of Public Health, National Virology Reference Laboratory, Ankara, Turkey
| | - Yasemin Coşgun
- Republic of Turkey Ministry of Health, General Directorate of Public Health, National Virology Reference Laboratory, Ankara, Turkey
| | - Ömer Şahin
- Kırıkkale University Faculty of Medicine, Department of Infection Disease and Clinical Microbiology, Kirikkale, Turkey
| | - Ferhat Arslan
- Kırıkkale University Faculty of Medicine, Department of Infection Disease and Clinical Microbiology, Kirikkale, Turkey
| |
Collapse
|
9
|
Nanthapisal S, Puthanakit T, Jaru-Ampornpan P, Nantanee R, Sodsai P, Himananto O, Sophonphan J, Suchartlikitwong P, Hiransuthikul N, Angkasekwinai P, Tangsathapornpong A, Hirankarn N. A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines. Vaccine 2022; 40:2551-2560. [PMID: 35341647 PMCID: PMC8947780 DOI: 10.1016/j.vaccine.2022.03.036] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2022] [Revised: 03/02/2022] [Accepted: 03/14/2022] [Indexed: 12/04/2022]
Abstract
Background Immunogenicity of inactivated SARS-CoV-2 vaccine has waning antibody over time. With the emergence of the SARS-CoV-2 delta variant, which requires higher neutralizing antibody to prevent infection, a booster dose is needed. Objective To evaluate immunogenicity and reactogenicity of standard- versus low-dose ChAdOx1 nCoV-19 vaccine booster after CoronaVac in healthy adults. Methods A double-blinded, randomized, controlled trial of adult, aged 18–59 years, with completion of 2-dose CoronaVac at 21–28 days apart for more than 2 months was conducted. Participants were randomized to receive AZD1222 (Oxford/AstraZeneca) intramuscularly; standard dose (SD, 5x1010 viral particles) or low dose (LD, 2.5x1010 viral particles). Surrogate virus neutralization test (sVNT) against wild type and delta variant, and anti-spike-receptor-binding-domain IgG (anti-S-RBD IgG) were compared as geometric mean ratio (GMR) at day 14 and 90 between LD and SD arms. Results From July-August 2021, 422 adults with median age of 44 (IQR 36–51) years were enrolled. The median interval from CoronaVac to AZD1222 booster was 77 (IQR 64–95) days. At baseline, geometric means (GMs) of sVNT against delta variant and anti-S-RBD IgG were 18.1%inhibition (95% CI 16.4–20.0) and 111.5 (105.1–118.3) BAU/ml. GMs of sVNT against delta variant and anti-S-RBD IgG in SD were 95.6%inhibition (95% CI 94.3–97.0) and 1975.1 (1841.7–2118.2) BAU/ml at day 14, and 89.4%inhibition (86.4–92.4) and 938.6 (859.9–1024.4) BAU/ml at day 90, respectively. GMRs of sVNT against delta variant and anti-S-RBD IgG in LD compared to SD were 1.00 (95% CI 0.98–1.02) and 0.84 (0.76–0.93) at day 14, and 0.98 (0.94–1.03) and 0.89 (0.79–1.00) at day 90, respectively. LD recipients had significantly lower rate of fever (6.8% vs 25.0%) and myalgia (51.9% vs 70.7%) compared to SD. Conclusion Half-dose AZD1222 booster after 2-dose inactivated SARS-CoV-2 vaccination had non-inferior immunogenicity, yet lower systemic reactogenicity. Fractional low-dose AZD1222 booster should be considered especially in resource-constrained settings.
Collapse
Affiliation(s)
- Sira Nanthapisal
- Department of Pediatrics, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand; Research Unit in Infectious and Immunology, Faculty of Medicine, Thammasat University, Pathumthani, Thailand; Clinical Research Center, Faculty of Medicine, Thammasat University, Pathumthani, Thailand
| | - Thanyawee Puthanakit
- Center of Excellence in Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
| | - Peera Jaru-Ampornpan
- Virology and Cell Technology Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC)
| | - Rapisa Nantanee
- Center of Excellence in Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Pediatric Allergy and Clinical Immunology Research Unit, Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
| | - Pimpayao Sodsai
- Center of Excellence in Immunology and Immune-mediated Diseases, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
| | - Orawan Himananto
- Monoclonal Antibody Production and Application Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC)
| | - Jiratchaya Sophonphan
- The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), The Thai Red Cross AIDS Research Centre, Bangkok, Thailand
| | - Pintip Suchartlikitwong
- Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
| | - Narin Hiransuthikul
- Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
| | - Pornpimon Angkasekwinai
- Department of Medical Technology, Faculty of Allied Health Sciences, Thammasat University, Pathumthani, Thailand; Research Unit in Molecular Pathogenesis and Immunology of Infectious Diseases, Thammasat University, Pathumthani, Thailand; Research Unit in Infectious and Immunology, Faculty of Medicine, Thammasat University, Pathumthani, Thailand
| | - Auchara Tangsathapornpong
- Department of Pediatrics, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand; Research Unit in Infectious and Immunology, Faculty of Medicine, Thammasat University, Pathumthani, Thailand
| | - Nattiya Hirankarn
- Center of Excellence in Immunology and Immune-mediated Diseases, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
| | | |
Collapse
|
10
|
Martinez-Acuña N, Avalos-Nolazco DM, Rodriguez-Rodriguez DR, Martinez-Liu CG, Galan-Huerta KA, Padilla-Rivas GR, Ramos-Jimenez J, Ayala-de-la-Cruz S, Cienfuegos-Pecina E, Diaz-Chuc EA, Cazares-Tamez R, Flores-Arechiga A, Perez-Chavez F, Arellanos-Soto D, Lozano-Sepulveda SA, Garza-Gonzalez E, Treviño-Garza C, Montes-de-Oca-Luna R, Lee-Gonzalez AB, de-la-O-Cavazos ME, Rivas-Estilla AM. Seroprevalence of Anti-SARS-CoV-2 Antibodies in Blood Donors from Nuevo Leon State, Mexico, during 2020: A Retrospective Cross-Sectional Evaluation. Viruses 2021; 13:1225. [PMID: 34202849 PMCID: PMC8310175 DOI: 10.3390/v13071225] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2021] [Revised: 06/11/2021] [Accepted: 06/15/2021] [Indexed: 01/19/2023] Open
Abstract
The progression and distribution of the SARS-CoV-2 pandemic are continuously changing over time and can be traced by blood donors' serological survey. Here, we investigated the seroprevalence of anti-SARS-CoV-2 antibodies in blood donors in Nuevo Leon, Mexico during 2020 as a strategy for the rapid evaluation of the spread of SARS-CoV-2 and asymptomatic case detection. We collected residual plasma samples from blood donors who attended two regional donation centers from January to December of 2020 to identify changes in anti-SARS-CoV-2 IgG prevalence. Plasma samples were analyzed on the Abbott Architect instrument using the commercial Abbott SARS-CoV-2 IgG chemiluminescent assay. We found a total of 99 reactive samples from 2068 analyzed plasma samples, resulting in a raw prevalence of 4.87%. Donors aged 18-49 years were more likely to be seropositive compared to those aged >50 years (p < 0.001). Weekly seroprevalence increased from 1.8% during the early pandemic stage to 27.59% by the end of the year. Prevalence was 1.46-fold higher in females compared to males. Case geographical mapping showed that Monterrey city recorded the majority of SARS-CoV-2 cases. These results show that there is a growing trend of seroprevalence over time associated with asymptomatic infection that is unnoticed under the current epidemiological surveillance protocols.
Collapse
Affiliation(s)
- Natalia Martinez-Acuña
- Department of Biochemistry and Molecular Medicine, School of Medicine, Autonomous University of Nuevo León, Monterrey 64460, Mexico; (N.M.-A.); (D.M.A.-N.); (D.R.R.-R.); (C.G.M.-L.); (K.A.G.-H.); (G.R.P.-R.); (D.A.-S.); (S.A.L.-S.); (E.G.-G.)
- Center of Research and Innovation on Medical Virology, School of Medicine, Autonomous University of Nuevo Leon, Monterrey 64460, Mexico;
| | - Diana Minerva Avalos-Nolazco
- Department of Biochemistry and Molecular Medicine, School of Medicine, Autonomous University of Nuevo León, Monterrey 64460, Mexico; (N.M.-A.); (D.M.A.-N.); (D.R.R.-R.); (C.G.M.-L.); (K.A.G.-H.); (G.R.P.-R.); (D.A.-S.); (S.A.L.-S.); (E.G.-G.)
| | - Diana Raquel Rodriguez-Rodriguez
- Department of Biochemistry and Molecular Medicine, School of Medicine, Autonomous University of Nuevo León, Monterrey 64460, Mexico; (N.M.-A.); (D.M.A.-N.); (D.R.R.-R.); (C.G.M.-L.); (K.A.G.-H.); (G.R.P.-R.); (D.A.-S.); (S.A.L.-S.); (E.G.-G.)
| | - Cynthia Gabriela Martinez-Liu
- Department of Biochemistry and Molecular Medicine, School of Medicine, Autonomous University of Nuevo León, Monterrey 64460, Mexico; (N.M.-A.); (D.M.A.-N.); (D.R.R.-R.); (C.G.M.-L.); (K.A.G.-H.); (G.R.P.-R.); (D.A.-S.); (S.A.L.-S.); (E.G.-G.)
- Center of Research and Innovation on Medical Virology, School of Medicine, Autonomous University of Nuevo Leon, Monterrey 64460, Mexico;
| | - Kame Alberto Galan-Huerta
- Department of Biochemistry and Molecular Medicine, School of Medicine, Autonomous University of Nuevo León, Monterrey 64460, Mexico; (N.M.-A.); (D.M.A.-N.); (D.R.R.-R.); (C.G.M.-L.); (K.A.G.-H.); (G.R.P.-R.); (D.A.-S.); (S.A.L.-S.); (E.G.-G.)
- Center of Research and Innovation on Medical Virology, School of Medicine, Autonomous University of Nuevo Leon, Monterrey 64460, Mexico;
| | - Gerardo Raymundo Padilla-Rivas
- Department of Biochemistry and Molecular Medicine, School of Medicine, Autonomous University of Nuevo León, Monterrey 64460, Mexico; (N.M.-A.); (D.M.A.-N.); (D.R.R.-R.); (C.G.M.-L.); (K.A.G.-H.); (G.R.P.-R.); (D.A.-S.); (S.A.L.-S.); (E.G.-G.)
| | - Javier Ramos-Jimenez
- Center of Research and Innovation on Medical Virology, School of Medicine, Autonomous University of Nuevo Leon, Monterrey 64460, Mexico;
- Department of Internal Medicine, Infectious Disease Service, Hospital Universitario “Dr. Jose E. Gonzalez”, Autonomous University of Nuevo León, Monterrey 64460, Mexico
| | - Sergio Ayala-de-la-Cruz
- Department of Clinical Pathology and Blood Transfusion Bank, Hospital Universitario “Dr. Jose E. Gonzalez”, Autonomous University of Nuevo León, Monterrey 64460, Mexico; (S.A.-d.-l.-C.); (E.C.-P.); (E.A.D.-C.); (R.C.-T.); (A.F.-A.); (F.P.-C.)
| | - Eduardo Cienfuegos-Pecina
- Department of Clinical Pathology and Blood Transfusion Bank, Hospital Universitario “Dr. Jose E. Gonzalez”, Autonomous University of Nuevo León, Monterrey 64460, Mexico; (S.A.-d.-l.-C.); (E.C.-P.); (E.A.D.-C.); (R.C.-T.); (A.F.-A.); (F.P.-C.)
| | - Erik Alejandro Diaz-Chuc
- Department of Clinical Pathology and Blood Transfusion Bank, Hospital Universitario “Dr. Jose E. Gonzalez”, Autonomous University of Nuevo León, Monterrey 64460, Mexico; (S.A.-d.-l.-C.); (E.C.-P.); (E.A.D.-C.); (R.C.-T.); (A.F.-A.); (F.P.-C.)
| | - Rogelio Cazares-Tamez
- Department of Clinical Pathology and Blood Transfusion Bank, Hospital Universitario “Dr. Jose E. Gonzalez”, Autonomous University of Nuevo León, Monterrey 64460, Mexico; (S.A.-d.-l.-C.); (E.C.-P.); (E.A.D.-C.); (R.C.-T.); (A.F.-A.); (F.P.-C.)
| | - Amador Flores-Arechiga
- Department of Clinical Pathology and Blood Transfusion Bank, Hospital Universitario “Dr. Jose E. Gonzalez”, Autonomous University of Nuevo León, Monterrey 64460, Mexico; (S.A.-d.-l.-C.); (E.C.-P.); (E.A.D.-C.); (R.C.-T.); (A.F.-A.); (F.P.-C.)
| | - Fernando Perez-Chavez
- Department of Clinical Pathology and Blood Transfusion Bank, Hospital Universitario “Dr. Jose E. Gonzalez”, Autonomous University of Nuevo León, Monterrey 64460, Mexico; (S.A.-d.-l.-C.); (E.C.-P.); (E.A.D.-C.); (R.C.-T.); (A.F.-A.); (F.P.-C.)
| | - Daniel Arellanos-Soto
- Department of Biochemistry and Molecular Medicine, School of Medicine, Autonomous University of Nuevo León, Monterrey 64460, Mexico; (N.M.-A.); (D.M.A.-N.); (D.R.R.-R.); (C.G.M.-L.); (K.A.G.-H.); (G.R.P.-R.); (D.A.-S.); (S.A.L.-S.); (E.G.-G.)
- Center of Research and Innovation on Medical Virology, School of Medicine, Autonomous University of Nuevo Leon, Monterrey 64460, Mexico;
| | - Sonia Amelia Lozano-Sepulveda
- Department of Biochemistry and Molecular Medicine, School of Medicine, Autonomous University of Nuevo León, Monterrey 64460, Mexico; (N.M.-A.); (D.M.A.-N.); (D.R.R.-R.); (C.G.M.-L.); (K.A.G.-H.); (G.R.P.-R.); (D.A.-S.); (S.A.L.-S.); (E.G.-G.)
- Center of Research and Innovation on Medical Virology, School of Medicine, Autonomous University of Nuevo Leon, Monterrey 64460, Mexico;
| | - Elvira Garza-Gonzalez
- Department of Biochemistry and Molecular Medicine, School of Medicine, Autonomous University of Nuevo León, Monterrey 64460, Mexico; (N.M.-A.); (D.M.A.-N.); (D.R.R.-R.); (C.G.M.-L.); (K.A.G.-H.); (G.R.P.-R.); (D.A.-S.); (S.A.L.-S.); (E.G.-G.)
| | - Consuelo Treviño-Garza
- Department of Pediatrics, Hospital Universitario “Dr. Jose E. Gonzalez”, Autonomous University of Nuevo León, Monterrey 64460, Mexico; (C.T.-G.); (M.E.d.-l.-O.-C.)
- Secretariat of Health of Nuevo León State, Monterrey 64460, Mexico; (R.M.-d.-O.-L.); (A.B.L.-G.)
| | - Roberto Montes-de-Oca-Luna
- Secretariat of Health of Nuevo León State, Monterrey 64460, Mexico; (R.M.-d.-O.-L.); (A.B.L.-G.)
- Department of Histology, School of Medicine, Hospital Universitario “Dr. Jose E. Gonzalez”, Autonomous University of Nuevo León, Monterrey 64460, Mexico
| | - Aurora Beatriz Lee-Gonzalez
- Secretariat of Health of Nuevo León State, Monterrey 64460, Mexico; (R.M.-d.-O.-L.); (A.B.L.-G.)
- Transfusion Center, CETS, Secretariat of Health of Nuevo Leon State, Monterrey 64460, Mexico
| | - Manuel Enrique de-la-O-Cavazos
- Department of Pediatrics, Hospital Universitario “Dr. Jose E. Gonzalez”, Autonomous University of Nuevo León, Monterrey 64460, Mexico; (C.T.-G.); (M.E.d.-l.-O.-C.)
- Secretariat of Health of Nuevo León State, Monterrey 64460, Mexico; (R.M.-d.-O.-L.); (A.B.L.-G.)
| | - Ana Maria Rivas-Estilla
- Department of Biochemistry and Molecular Medicine, School of Medicine, Autonomous University of Nuevo León, Monterrey 64460, Mexico; (N.M.-A.); (D.M.A.-N.); (D.R.R.-R.); (C.G.M.-L.); (K.A.G.-H.); (G.R.P.-R.); (D.A.-S.); (S.A.L.-S.); (E.G.-G.)
- Center of Research and Innovation on Medical Virology, School of Medicine, Autonomous University of Nuevo Leon, Monterrey 64460, Mexico;
| |
Collapse
|
11
|
Saple P, Gosavi S, Pawar T, Chaudhari G, Mahale H, Deshmukh P, Kurundkar A, Pedgaonkar S, Thakare S. Seroprevalence of anti-SARS-CoV-2 of IgG antibody by ELISA: Community-based, cross-sectional study from urban area of Malegaon, Maharashtra. J Family Med Prim Care 2021; 10:1453-1458. [PMID: 34041193 PMCID: PMC8140273 DOI: 10.4103/jfmpc.jfmpc_2191_20] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2020] [Revised: 12/09/2020] [Accepted: 12/21/2020] [Indexed: 11/25/2022] Open
Abstract
Background: Given the high incidence of asymptomatic or subclinical SARS-CoV-2 infection, reported cases likely underestimate the overall prevalence and infectivity of COVID-19. Serological test for IgG can provide a better measure of disease activity by identifying asymptomatic or subclinical infection. This study was conducted to estimate the seroprevalence of SARS-CoV-2 infection and to the determinants of SARS-CoV-2 infection in the hotspot area of COVID-19. Method: It was a community-based, cross-sectional study using multistage sampling with a sample size of 360. After informed consent, the demographic information, past history of SARI/ILI, contact, COVID-19 status were collected. The blood samples were taken from one family member for anti-SARS-CoV-2 IgG antibody by ELISA testing kit. Results: Majority of the study subjects had no history of SARI (86%) or any contact with COVID-19 case (98%). Overall seroprevalence of anti-SARS-CoV-2 of IgG antibody was 40% (95% CI 35–45%), infection fatality rate (IFR) was 0.7%. Seroprevalence varied significantly depending on religious background; with Muslims (53%) seroprevalence compared to other religious groups. Seroprevalence of homemaker/unemployed (49%) and laborer (55%) was significantly higher compared to business (30%) and service occupation (21%). Subjects with overcrowding conditions and poor ventilation was significantly associated with higher seroprevalence with odds ratio of 2.5 and 2.3, respectively. Conclusion: The antibody testing detects a large number of asymptomatic cases or previously infected cases which would have been missed by clinical history. Thus, the number of undiagnosed cases was found significantly higher even with rigorous implementation of lockdown.
Collapse
Affiliation(s)
- Pallavi Saple
- Shri Bhausaheb Hire Government Medical College, (SBHGMC), Dhule, Maharashtra, India
| | - Shriram Gosavi
- Department of Community Medicine, SBHGMC, Dhule, Maharashtra, India
| | - Tushar Pawar
- Department of Surgery, SBHGMC, Dhule, Maharashtra, India
| | | | | | | | - Ashish Kurundkar
- Department of Pathology, Medical University of South Carolina, USA
| | - Sarang Pedgaonkar
- International Institute for Population Sciences (IIPS), Mumbai, Maharashtra, India
| | - Sapana Thakare
- Medical Officer of Health (MOH), Municipal Corporation of Malegaon, Maharashtra, India
| |
Collapse
|
12
|
Selingerova I, Valik D, Gescheidtova L, Sramek V, Cermakova Z, Zdrazilova-Dubska L. Interpretive discrepancies caused by target values inter-batch variations in chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG by MAGLUMI. J Med Virol 2020; 93:1805-1809. [PMID: 33079389 DOI: 10.1002/jmv.26612] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2020] [Revised: 10/06/2020] [Accepted: 10/12/2020] [Indexed: 11/11/2022]
Abstract
Plasma specimens from coronavirus disease 2019 patients were double-tested for anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies by two different batches of MAGLUMI 2019-nCov immunoglobulin M/immunoglobulin G (IgM/IgG) assays to evaluate IgM/IgG levels, qualitative interpretation, antibody kinetics, and linearity of diluted specimen. Here we show that (i) high-level IgM specimens need to be diluted with negative human plasma but not kit diluents and (ii) measured anti-SARS-CoV-2 IgM/IgG concentrations are substantially higher with later marketed immunoassay batch leading to (iii) the change of qualitative interpretation (positive vs. negative) in 12.3% of specimens measured for IgM, (iv) the informative time-course pattern of antibody production only when data from different immunoassay batches are not combined.
Collapse
Affiliation(s)
- Iveta Selingerova
- Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic
| | - Dalibor Valik
- Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic.,Department of Clinical Biochemistry, University Hospital Brno, Brno, Czech Republic
| | - Lenka Gescheidtova
- Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic
| | - Vladimir Sramek
- Department of Anaesthesiology, St Anne's University Hospital, Brno, Czech Republic
| | - Zdenka Cermakova
- Department of Clinical Biochemistry, University Hospital Brno, Brno, Czech Republic
| | - Lenka Zdrazilova-Dubska
- Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic.,Department of Clinical Microbiology and Immunology, University Hospital Brno, Brno, Czech Republic
| |
Collapse
|